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Chronic infection is one of the major causes of cancer, and there are several
mechanisms for infection-mediated oncogenesis. Some pathogens encode gene
products that behave like oncogenic factors, hijacking cellular pathways to pro-
mote the survival and proliferation of infected cells in vivo. Some of these viral
oncoproteins trigger a cellular damage defense response leading to senescence;
however, other viral factors hinder this suppressive effect, suggesting that cooper-
ation of those viral factors is important for malignant transformation. Coinfection
with multiple agents is known to accelerate cancer development in certain cases.
For example, parasitic or bacterial infection is a risk factor for adult T-cell leuke-
mia-lymphoma induced by human T-cell leukemia virus type 1, and Epstein-Barr
virus and malaria are closely associated with endemic Burkitt lymphoma. Human
immunodeficiency virus type 1 infection is accompanied by various types of infec-
tion-related cancer. These findings indicate that these oncogenic pathogens can
cooperate to overcome host barriers against cancer development. In this review,
the authors focus on the collaborative strategies of pathogens for oncogenesis
from two different points of view: (i) the cooperation of two or more different
factors encoded by a single pathogen; and (ii) the acceleration of oncogenesis by
coinfection with multiple agents.
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1 | INTRODUCTION
Infection is an important cause of human malignant diseases. It is
estimated that approximately 15% of cancer cases worldwide are
attributable to infection with oncogenic pathogens.1 The IARC has
classified 7 viruses, 1 bacterium, and 3 parasites as well estab-
lished (Group 1) carcinogenic agents based on sufficient evidence
in humans: HBV, HCV, HPV (high-risk types), EBV, KSHV, HIV,
HTLV-1, Helicobacter pylori, Opisthorchis viverrini, Clonorchis sinensis,
and Schistosoma haematobium (Table 1).2 These pathogens con-
tribute to oncogenesis by several distinct actions. Pathogens that
Abbreviations: AID, activation-induced cytidine deaminase; ATL, adult T-cell leukemia-
lymphoma; BCR, B-cell receptor; BL, Burkitt lymphoma; DDR, DNA damage response; eBL,
endemic Burkitt lymphoma; EBV, Epstein-Barr virus; EGFR, epidermal growth factor
receptor; GC, germinal center; HBV, hepatitis B virus; HBZ, HTLV-1 bZIP factor; HCC,
hepatocellular carcinoma; HCV, hepatitis C virus; HHV, human herpesviruses; HIV, human
immunodeficiency virus; HL, Hodgkin lymphoma; HPV, human papillomavirus; HTLV-1,
human T-cell leukemia virus type 1; IARC, International Agency for Research on Cancer;
IDH, infective dermatitis associated with HTLV-1; IL, interleukin; KS, Kaposi's sarcoma;
KSHV, Kaposi's sarcoma-associated herpesvirus; MCC, Merkel cell carcinoma; NF-κB,
nuclear factor kappa B; NHL, non-Hodgkin lymphoma; OIS, oncogene-induced senescence;
PEL, primary effusion lymphoma; ROS, reactive oxygen species; TCR, T-cell receptor;
TIGIT, T-cell immunoreceptor with Ig and ITIM domains; Treg, regulatory T cells.
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productively replicate in vivo, such as HBV, HCV, H. pylori, and
the parasites, cause tissue inflammation, leading to the accumula-
tion of damage in host cells.3-7 In contrast, EBV, KSHV, HPV, and
HTLV-1 establish latent infection, and most individuals infected
with these viruses are asymptomatic.8-11 Each of these latent
viruses encodes its own oncogene(s); however, these oncogenes
are tightly regulated and selectively expressed in cancer cells
in vivo. Finally, HIV is unique among the pathogens categorized in
IARC’s Group 1, as it doesn’t have oncogenic potential itself, but
it increases cancer risk by allowing other oncogenic agents to
propagate in coinfected subjects.1,12 Collectively, infectious agents
are thought to cause cancer by one or more of the following
mechanisms: persistent inflammation, potent oncogenic activity,
and promoting escape from host immunity. The first mechanism
(inflammation) is reviewed elsewhere.13,14 We will begin this dis-
cussion by focusing on the second mechanism (oncogenic factors
produced by pathogens), and then we will discuss how various
pathogens (including HIV) can interact with one another to further
increase the risk of cancer.
2 | COLLABORATION OF VIRAL FACTORS
ALLOWS PROLIFERATION OF INFECTED
CELLS WITH DNA DAMAGE: POSSIBLE
MECHANISM OF MALIGNANT
TRANSFORMATION
Viral oncogenes play important roles in the persistent proliferation
and survival of infected cells, resulting in malignant transformation. It
is known that the potent activity of any of several viral oncoproteins
would normally induce the cellular DDR, leading to apoptosis or OIS.
Subversion of the OIS pathway15 by the collaboration of two or
more viral factors is a common mechanism that drives the increase
in infected cells with genetic abnormalities.
2.1 | HTLV-1 Tax and HBZ
Human T-cell leukemia virus type 1 is a retrovirus that induces a malig-
nant disease of CD4+ T cells, ATL.16 The HTLV-1 provirus is integrated
into the host genome and encodes several regulatory and accessory
TABLE 1 Infectious agents categorized as Groups 1 and 2 by the International Agency for Research on Cancer (IARC) Monograph2
IARC Group Biological agent Main malignant diseases
1 Virus Hepatitis B virus HCC
1 Hepatitis C virus HCC, NHL
1 HIV-1 NHL, KS, HL, MCC
1 HTLV-1 ATL
1 EBV BL, NHL, HL, NK/T lymphoma,
nasopharyngeal ca, gastric ca
1 KSHV KS, PEL
1 HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 Cervical ca, anogenital ca,
head and neck ca
1 Bacterium Helicobacter pylori Gastric ca, MALT lymphoma
1 Parasite Schistosoma haematobium Bladder ca
1 Opisthorchis viverrini Cholangiocarcinoma
1 Clonorchis sinensis Cholangiocarcinoma
2A Virus HPV type 68 Cervical ca
2A Merkel cell polyomavirus (MCPyV) MCC
2A Parasite Malaria (Plasmodium falciparum) BL
2B Virus HIV-2
2B HPV 26, 30, 34, 53, 66, 67, 69, 70, 73, 82, 85, 97
2B HPV 5 and 8 of genera beta
2B BK polyomavirus (BKV)
2B JC polyomavirus (JCV)
2B Parasite Schistosoma japonicum
IARC has classified 7 viruses, 1 bacterium, and 3 parasites as Group 1, and another 7 viruses and 2 parasites as Group 2. Group 1, oncogenic to humans;
Group 2A, probably oncogenic to humans; Group 2B, possibly oncogenic to humans.
ATL, adult T-cell leukemia-lymphoma; BL, Burkitt lymphoma; ca, cancer; EBV, Epstein-Barr virus; HCC, hepatocellular carcinoma; HIV, human immunode-
ficiency virus; HL, Hodgkin lymphoma; HPV, human papillomavirus; HTLV-1, human T-cell leukemia virus type 1; IARC, International Agency for
Research on Cancer; KS, Kaposi’s sarcoma; KSHV, Kaposi’s sarcoma-associated herpesvirus; MALT, mucosa-associated lymphoid tissue; MCC, Merkel cell
carcinoma; NHL, non-Hodgkin lymphoma; NK/T lymphoma, natural killer/T-cell lymphoma; PEL, primary effusion lymphoma.
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genes that regulate viral replication.17,18 Among them, Tax and HBZ
(Figure 1A) are important for the persistence of HTLV-1 in vivo,
although they have different roles in its propagation. Viral replication
depends on Tax, and Tax is thus crucial to de novo infection by the
virus. In contrast, HBZ is critical for clonal proliferation of infected
cells.19,20 Both Tax and HBZ possess oncogenic potential;18,21 however,
they have opposite functions in many signaling pathways (Figure 1B).
Tax strongly activates both the canonical and non-canonical NF-jB
pathways mainly through activation of IKK complex,17,22-24 whereas
HBZ specifically suppresses the canonical NF-jB pathway by inhibiting
p65/RelA;25 Tax activates the CREB pathway and HBZ suppresses it by
competitive binding to CREB family proteins;26 and Tax activates the
Wnt/b-catenin cascade, but HBZ inhibits this signaling pathway by sup-
pressing the downstream transcription factors TCF1 and LEF1.27 These
findings suggest that Tax and HBZ can fine-tune the regulation of these
pathways by counteracting one another.
As Tax is a potent oncoprotein, it triggers an oncogenic stress
response in the expressing cells and, consequently, induces cell cycle
arrest and senescence in a way that is similar to OIS triggered by
Ras28 and c-Myc (Figure 2A).29 Kinjo et al30 reported that Tax
induces DNA damage through the generation of intracellular ROS
and, consequently, leads to senescence in primary human cells. It
has also been shown that hyper-activation of NF-jB by Tax induces
cellular senescence.31,32 Importantly, HBZ can release Tax-expressing
cells from cell cycle arrest, probably by inhibition of canonical NF-jB
signaling.25,31 In addition, both Tax and HBZ have a potential to inhi-
bit DNA repair.11,17 These observations suggest that these two viral
factors facilitate the clonal expansion of infected cells even in the
presence of genetic aberrations.
Tax is a highly immunogenic protein, and therefore it is a main tar-
get of CTL.33-35 In addition, Tax might be involved in the emergence
of neoantigens in ATL cells, as it has clastogenic and genotoxic poten-
tial.17,30,36 Thus, Tax evokes a host immune reaction against HTLV-1-
infected and ATL cells. In contrast, HBZ is closely associated with
immune-suppressive phenotypes of infected cells. HBZ potently
enhances transcription of Foxp3, which is a master gene of Treg and,
indeed, the number of Treg is significantly increased in HBZ-transgenic
mice and primary HTLV-1-infected and ATL cells.21,37,38 A recent
study demonstrated that HBZ induces a co-inhibitory receptor, TIGIT,
on the surface of T cells, and suppresses the immune response
through induction of IL-10 from dendritic cells.39 In addition, vaccina-
tion with Tax protein is less efficient in HBZ-transgenic mice than in
wild-type littermates.39 These results suggest that HBZ expressed in
infected cells can suppress anti-Tax immunity in vivo. Anti-HBZ CTL
are less frequent than anti-Tax CTL in HTLV-1-infected subjects
despite the constant expression of HBZ, implying that the immuno-
genicity of HBZ is low.40 In addition, HBZ suppresses the intracellular
inhibitory signal through TIGIT by inactivation of SHP-2 and, conse-
quently, enhances cell proliferation upon TCR stimulation.41 Taken
together, these reports indicate that Tax stimulates many oncogenic
pathways while HBZ counterbalances the negative effects of Tax,
leading to malignant transformation of infected cells.
2.2 | HPV E6 and E7
High-risk types of HPV are etiological agents of cervical, anal, and
head and neck cancers. The IARC has classified 12 types of HPV
(HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) as Group 1
F IGURE 1 Human T-cell leukemia virus type 1 (HTLV-1) Tax and HTLV-1 bZIP factor (HBZ) counteract one another. (A) HTLV-1 Tax and
HBZ are encoded in the plus and the minus strand of HTLV-1 provirus, respectively. (B) These two factors counteract one another in many
signaling pathways. Representative examples of cellular proteins targeted by Tax and/or HBZ are shown. NF-jB, nuclear factor kappa B;
TGF-b, transforming growth factor beta
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carcinogenic agents.1 The products of two early genes encoded in
HPV, E6 and E7, are constitutively expressed in HPV-positive tumor
cells and play major roles in oncogenesis by HPV. It is well known
that E6 and E7 inactivate the cellular tumor suppressors p53 and
retinoblastoma tumor suppressor protein (pRb) respectively (Fig-
ure 2B).42 The transforming activity of E7 is strongly increased in
the presence of E6. E7 triggers a carcinogenic cascade by binding to
pRb and inactivating it; the resulting activation of E2F transcription
factors promotes cell proliferation. Overactive E2Fs would normally
cause p53 activation and induce apoptosis or senescence as a cellu-
lar defense response; however, the E6/E6-associated protein (E6AP)
complex ubiquitinates p53 for proteasomal degradation. Thus, the
sequential effects of E7 and E6 trigger oncogenesis in HPV-infected
cells. It has also been reported that high-risk, but not low-risk, HPV
E7 causes p16INK4A induction in a pRb-independent way – a phe-
nomenon that is also observed in Ras-mediated OIS.43,44 A recent
genomic sequencing study showed that the sequence of HPV16 E7
is strictly conserved in precancerous and cancerous tissues,
suggesting its importance in carcinogenesis.45 Collectively, these
studies show that persistent replicative stresses from E7 and inhibi-
tion of cell cycle arrest and senescence by E6 induce the accumula-
tion of genetic aberrations and, consequently, increase the
probability of malignant transformation by HPV. It is also known that
HPV E5 protein has oncogenic properties; it promotes cell prolifera-
tion by stimulation of EGFR, and suppresses TRAIL- and FasL-
mediated apoptosis.46,47 In addition, E5 downregulates expression of
MHC class I, class II, and CD1d on the surface of infected cells,
enabling them to escape from CTL and NKT cells.46 Thus, E5 plays
important collaborative roles in HPV-mediated carcinogenesis, espe-
cially by modulation of host immune systems.
2.3 | EBV oncoproteins
Human herpesviruses including EBV and KSHV establish latent infec-
tion in the host by expressing a limited number of gene products.48
This latency is reversible – the virus can resume productive viral
F IGURE 2 Induction of viral oncogene-induced senescence and its subversion by multiple viral proteins. (A) Human T-cell leukemia virus
type 1 (HTLV-1) Tax and HTLV-1 bZIP factor (HBZ). (B) Human papillomavirus (HPV) E6 and E7. (C) Epstein-Barr virus (EBV) EBNA-2, EBNA-
LP, and EBNA-3c. (D) Kaposi’s sarcoma-associated herpesvirus (KSHV) v-cyclin and vFLIP. DDR, DNA damage response; NF-jB, nuclear factor
kappa B; ROS, reactive oxygen species
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replication (the so-called lytic phase) – and, in both phases, HHV
induce DDR to remodel the infected cells.49 After B cells become
infected with EBV, the viral nuclear antigens EBNA2 and EBNA-LP
are immediately expressed, and they upregulate cellular growth-pro-
moting genes such as c-Myc and CD23 (Figure 2C).50 Hyper-prolif-
eration of B cells induced by these viral factors triggers replication-
mediated DNA damage and, consequently, the cellular DDR would
suppress cell proliferation. However, another EBV oncoprotein,
EBNA3C, inhibits DDR signaling and promotes proliferation and
immortalization of the infected cell, suggesting that EBNA2,
EBNA-LP, and EBNA3C cooperate with each other in cellular
transformation.
Two latent membrane proteins, LMP-1 and LMP-2A, are major
EBV-encoded oncoproteins, and mimic CD40 and BCR signaling,
respectively.51 LMP-1 stimulates several oncogenic signaling path-
ways such as the NF-jB and MAPK pathways.52 LMP-2A constitu-
tively activates the Ras/PI3K/Akt pathway, and mediates cellular
transformation.53 Interestingly, a transgenic mouse model, which co-
expresses LMP-1 and LMP-2A in B cells, showed that LMP-2A
reduced hyperactivation of B cells induced by LMP-1.54 It is possible
that LMP-2A curbs overstimulation of oncogenic signals by LMP-1
to establish persistent infection in vivo.
2.4 | KSHV v-cyclin and vFLIP
Kaposi’s sarcoma-associated herpesvirus v-cyclin and vFLIP are
encoded in the same viral mRNA and expressed in latently infected
cells.48 v-cyclin accelerates cell cycle progression, triggers the DDR,
and finally induces autophagy and senescence in primary human
foreskin fibroblasts (Figure 2D). In contrast, a potent viral anti-apop-
totic factor, vFLIP, suppresses v-cyclin-induced senescence, con-
tributing to the expansion of KSHV-infected cells with DNA
damage.55 vFLIP also induces G1 arrest/senescence in HeLa cells
through hyperactivation of NF-jB that is reminiscent of Tax-
mediated senescence. In this setting, v-cyclin prevents cell cycle
arrest by vFLIP.56 It is suggested that these two proteins work in
concert to accelerate the transformation of KSHV-infected cells.
In summary, investigations of a variety of oncogenic viruses have
shown a common scheme: viral gene products collaborate to induce
proliferation while blocking senescence.
3 | ENHANCEMENT OF CANCER
DEVELOPMENT BY COINFECTION WITH
MULTIPLE AGENTS
Collaboration of viral gene products in oncogenesis is not limited
to gene products that all come from the same virus. In some
cases, coinfection with two or more pathogens is associated with
a higher cancer risk than infection with either of the pathogens
alone. Recent studies have shown a variety of molecular mecha-
nisms for this enhanced oncogenesis. Here, we summarize several
examples.
3.1 | Strongyloidiasis and infective dermatitis as
risk factors for ATL
Two types of superinfections are associated with an increased risk
of ATL in people already infected with HTLV-1. The first, strongy-
loidiasis, is a chronic parasitic infection of humans caused by
Strongyloides stercoralis. HTLV-1 proviral load is higher in S. sterco-
ralis-positive carriers than in non-coinfected subjects,57 and the inci-
dence of ATL is high in such superinfected subjects,58 suggesting
that S. stercoralis facilitates the clonal proliferation of HTLV-1-
infected cells. The second type of superinfection associated with
increased ATL risk is IDH: a refractory skin infection with Staphylo-
coccus aureus and/or beta-hemolytic Streptococci observed in HTLV-
1-infected children in developing countries.59 In IDH patients, HTLV-
1 proviral load is also higher60 and clonal expansion occurs at a
higher rate than in subjects infected with HTLV-1 only.61 A recent
study showed that clonal expansion and turnover of HTLV-1-
infected cells are increased in patients coinfected with S. sterco-
ralis.61 These observations suggest that coinfection with S. stercoralis
or IDH promotes both de novo infection and cell proliferation, which
depend on Tax and HBZ, respectively. This idea is compatible with
the fact that T-cell activation enhances the activities of Tax and
HBZ on cell proliferation in primary T cells.19,41,62 Thus, inflammation
and T-cell activation caused by the coinfective agent may increase
the risk of ATL development in HTLV-1 positive individuals.
3.2 | HIV-associated cancers
Human immunodeficiency virus 1 is rated a Group 1 oncogenic
agent by the IARC.2 HIV-1 induces AIDS and indirectly causes can-
cers by allowing other oncogenic pathogens to express. It is note-
worthy that HIV-1 infection is particularly closely associated with
several subtypes of NHL. Most AIDS-related NHL are of B-cell ori-
gin; it is suggested that depletion of CD4+ T cells by HIV-1 permits
dysregulation of B-cell expansion and the expression of B-lympho-
trophic viruses.63 EBV is detected in almost all cases of central ner-
vous system lymphoma, ~40% of diffuse large-cell lymphoma, and
~30% of BL. HL is also associated with coinfection by HIV-1 and
EBV. It has been reported that HIV-1-infected people have an
approximately 10-fold higher risk of developing HL than uninfected
people.64 The rate of EBV-positive HL is higher in HIV-1 infected
cases than in the general population,65 suggesting that EBV is closely
involved in the genesis of HIV-mediated HL. Importantly, the stan-
dard incidence rate of HL in HIV-infected subjects has increased
despite entering the era of combination antiretroviral therapy,
whereas that of NHL has dropped.66 These findings suggest that
there are distinct mechanisms of lymphomagenesis by EBV in the
presence of immune modulation by HIV, and that these mechanisms
vary between HL and NHL. KSHV67 and Merkel cell polyomavirus
(MCPyV)68 were first identified from cancer cells of AIDS-related
Kaposi’s sarcoma and Merkel-cell carcinoma respectively, and are
now recognized as causative agents of each cancer. KSHV is also
associated with a rare subtype of B-cell lymphoma, primary effusion
28 | YASUNAGA AND MATSUOKA
lymphoma (PEL), which occurs predominantly in the pleural or peri-
toneal cavity. The risk of HPV-associated cancers, such as cervical
cancer, anal cancer, and oropharyngeal cancer, is also elevated
among persons with AIDS.69
It is not surprising that immunosuppression by HIV allows malig-
nant transformation of host cells infected with other oncogenic
pathogens. However, a recent case study reported a rare “cancer-
like” malignant disease developed in an AIDS patient; tumors were
derived from cells of the tapeworm Hymenolepis nana.70 Characteris-
tics of this non-human origin tumor fulfilled the working definitions
of cancer: invasion and metastasis, hyperproliferative and monomor-
phic features, and genetic alterations (in H. nana’s genes). This case
demonstrated a novel mechanism for HIV-related tumorigenesis trig-
gered by another pathogen.
HIV-1 is also associated with several cancers that have not been
linked to other oncogenic pathogens. The risk of lung cancer is
higher in HIV-infected subjects than in the general population, and
the higher smoking rate in the HIV-infected population is one of the
factors explaining this trend.71 In addition, recent studies show that
immunosuppression by HIV and chronic inflammation are involved in
oncogenesis.72 It is known that HIV infection is a risk factor for can-
cers of the conjunctiva and the lip.12 Impairment of anti-cancer
immunity by HIV is a possible mechanism for the emergence of
these malignancies.
3.3 | EBV and malaria
Burkitt lymphoma (BL) is an aggressive B-cell malignancy originating
from a GC, and it can be classified into three subtypes according to
clinical features: endemic BL, sporadic BL, and HIV-associated BL.73
eBL is the most common childhood cancer in Africa, and more than
95% of cases are associated with EBV. In addition, it occurs at
higher incidence in areas in which malaria is endemic; therefore an
additional role of malaria in the etiology has long been suspected.74
Malaria is caused by several species of Plasmodium. A recent study
demonstrated that chronic infection with Plasmodium in mice pro-
motes clonal expansion of GC cells and induces expression of AID,
which is associated with genetic mutations and chromosomal
translocations.75 It is suggested that Plasmodium superinfection pro-
motes EBV-mediated oncogenesis by inducing genomic aberrations,
leading to the distinct B-cell malignancy, eBL.
3.4 | Helicobacter pylori and EBV
Most gastric cancers are associated with infection of gastric epithe-
lial cells with H. pylori.12 Helicobacter pylori is a highly heterogeneous
bacterium with a large genomic diversity. Helicobacter pylori strains
possessing the cagA gene are more virulent than cagA-negative
strains, and the CagA protein is closely linked to severe diseases
such as peptic ulcers and gastric cancer.76 EBV is also causally asso-
ciated with gastric carcinoma, and approximately 10% of cases con-
tain EBV in tumor cells.53 Recently, the mechanism of cooperative
oncogenesis by these two pathogens was clarified.77 CagA is
injected into gastric epithelial cells and interacts with the host tyro-
sine phosphatase SHP2, resulting in activation of SHP2, which is
important for oncogenesis by H. pylori. However, the SHP2 homo-
logue SHP1 inactivates CagA and thus prevents SHP2 activation.
EBV infection reduces the expression of SHP1 by inducing DNA
F IGURE 3 Schema of oncogenic processes mediated by collaboration of multiple pathogens. Cooperation of several pathogens can produce
malignant transformation by four processes: cell proliferation promoted by oncogenic factors in infected cells, chronic inflammation, coinfection
with certain combinations of pathogens, and immunodeficiency. EBV, Epstein-Barr virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV,
human immunodeficiency virus; HPV, human papillomavirus; HTLV-1, human T-cell leukemia virus type 1; KSHV, Kaposi’s sarcoma-associated
herpesvirus
YASUNAGA AND MATSUOKA | 29
hypermethylation in the SHP1 promoter region. Thus, EBV cancels
the negative effect of SHP1 on gastric carcinogenesis by H. pylori.
This may be a distinct mechanism of gastric cancer induced by dual
agents.
3.5 | Schistosoma haematobium and bacterial
infection
Schistosoma haematobium is endemic in sub-Saharan Africa and the
Middle East, and induces urinary bladder cancer.7,78 Bacterial superin-
fection is suggested to be a risk factor for S. haematobium-associated
bladder cancer. Schistosoma haematobium migrate into the bladder tis-
sue and cause chronic granulomatous inflammation in the mucosal
and submucosal layers of the bladder. The inflammation leads to the
development of squamous metaplasia and urine stasis, resulting in
bacterial infection. Some of the bacteria are thought to be associated
with the endogenous formation of carcinogenic N-nitrosamines in the
urinary tract. It is suggested that coinfection with S. haematobium and
these bacteria thus initiates oncogenic processes in the bladder.
4 | CONCLUDING REMARKS
In the present review, we summarized the mechanisms by which mul-
tiple pathogens can cooperate to cause cancer (Figure 3). Viral onco-
proteins encoded by HTLV-1, HPV, EBV, and KSHV promote cell
proliferation and subvert senescence within each infected cell (Fig-
ures 2 and 3). Chronic inflammation triggered by persistent infection
induces an accumulation of damage to tissue and DNA, and coinfec-
tion with certain pathogens accelerates oncogenesis. HIV infection
modifies the immune status of hosts coinfected with other oncogenic
agents, allowing malignant diseases to emerge. Thus, host immunity
plays a critical role in controlling infection-mediated cancers.
Understanding and appreciating the role of infectious agents in
oncogenesis is important for public health, as certain cancers are
theoretically preventable by infection control and prevention. The
majority of infection-mediated cancers occur in developing countries
(1.5 million in 1.9 million cases),12 suggesting that the number of
cancer cases can be reduced by appropriate medical strategies, such
as vaccination, antiviral treatments, antibiotics, antiparasitics, and
health education. Future research is needed to clarify the molecular
functions of the factors encoded in each pathogen, and to under-
stand their interactions with factors from other pathogens. It will be
beneficial to establish novel therapeutic/prophylactic strategies
against both infection-related cancers and chronic inflammatory dis-
eases caused by their etiological agents.
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